Diadema Partners Lp
Institutional manager — quarterly 13F holdings, Q ending 2026-03-31
Reported value
$587.7M
Q ending 2026-03-31
Prior quarter
$580.5M
Q ending 2025-12-31
Change
+1.2% QoQ · +53.3% YoY
Positions
144
reported holdings
Largest positions
Top 100 of 144 reported positions by value, Q ending 2026-03-31. A manager can hold shares, calls and puts on the same security at once — such positions are listed as separate rows. Type: Shares = common stock, Put/Call = option positions (valued at the underlying), Principal = debt. Tickers link to stock pages where covered.
| Holding | Ticker | Type | Value ▼ | Shares |
|---|---|---|---|---|
| Vertex Pharmaceuticals Inc | VRTX | Call | $41.6M | 93K |
| Liquidia Corporation | LQDA | Call | $25.0M | 662K |
| United Therapeutics Corp Del | UTHR | Call | $23.8M | 40K |
| Viking Therapeutics Inc | VKTX | Call | $21.5M | 659K |
| Capricor Therapeutics Inc | CAPR | Put | $19.0M | 623K |
| Apogee Therapeutics Inc | APGE | Call | $18.7M | 223K |
| Bridgebio Pharma Inc | BBIO 1.75 03/01/31 | Shares | $18.6M | 250K |
| Viking Therapeutics Inc | VKTX | Shares | $17.1M | 525K |
| United Therapeutics Corp Del | UTHR | Shares | $16.2M | 27K |
| Cytokinetics Inc | CYTK | Put | $13.2M | 200K |
| Johnson & Johnson | JNJ | Shares | $13.1M | 54K |
| Cogent Biosciences Inc | COGT | Shares | $12.4M | 323K |
| Revolution Medicines Inc | RVMD | Put | $12.2M | 126K |
| Merck & Co Inc | MRK | Put | $12.0M | 100K |
| United Therapeutics Corp Del | UTHR | Put | $11.9M | 20K |
| Abivax Sa | ABVX | Put | $11.1M | 100K |
| Abivax Sa | ABVX | Call | $11.1M | 100K |
| Jazz Pharmaceuticals Plc | Shares | $10.4M | 55K | |
| Capricor Therapeutics Inc | CAPR | Call | $10.0M | 329K |
| Incyte Corp | INCY | Put | $9.9M | 105K |
| Terns Pharmaceuticals Inc | 430 | Shares | $9.6M | 182K |
| Kodiak Sciences Inc | KOD | Put | $9.4M | 247K |
| Roivant Sciences Ltd | Put | $9.3M | 336K | |
| Biomarin Pharmaceutical Inc | BMRN | Shares | $8.4M | 148K |
| Abivax Sa | ABVX | Shares | $8.2M | 76K |
| Moderna Inc | MRNA | Put | $8.1M | 159K |
| Revolution Medicines Inc | RVMD | Shares | $7.9M | 81K |
| Kodiak Sciences Inc | KOD | Shares | $7.4M | 193K |
| Incyte Corp | INCY | Shares | $7.3M | 78K |
| Tg Therapeutics Inc | TGTX | Shares | $6.9M | 207K |
| Edgewise Therapeutics Inc | EWTX | Call | $6.7M | 213K |
| Corcept Therapeutics Inc | CORT | Call | $6.4M | 159K |
| Bridgebio Pharma Inc | BBIO | Shares | $6.3M | 85K |
| Structure Therapeutics Inc | GPCR | Put | $6.1M | 128K |
| Immunocore Hldgs Plc | IMCR | Shares | $5.8M | 193K |
| Eli Lilly & Co | LLY | Shares | $5.5M | 6K |
| Abbvie Inc | ABBV | Shares | $5.2M | 24K |
| Arcus Biosciences Inc | RCUS | Shares | $5.1M | 238K |
| Crispr Therapeutics Ag | Call | $5.1M | 106K | |
| Uniqure Nv | Put | $4.9M | 299K | |
| Corbus Pharmaceuticals Hldgs | CRBP | Shares | $4.1M | 440K |
| Uniqure Nv | Call | $4.1M | 250K | |
| Corvus Pharmaceuticals Inc | CRVS | Shares | $3.6M | 245K |
| Zymeworks Inc | ZYME | Shares | $3.6M | 142K |
| Replimune Group Inc | REPL | Put | $3.5M | 460K |
| Structure Therapeutics Inc | GPCR | Shares | $3.5M | 72K |
| Cytokinetics Inc | CYTK | Call | $3.3M | 50K |
| Vaxcyte Inc | PCVX | Call | $3.1M | 53K |
| Monte Rosa Therapeutics Inc | GLUE | Shares | $3.1M | 187K |
| Tenax Therapeutics Inc | TENX | Shares | $2.9M | 180K |
| Biohaven Ltd | Call | $2.7M | 317K | |
| Harmony Biosciences Hldgs In | HRMY | Shares | $2.6M | 93K |
| Intellia Therapeutics Inc | NTLA | Call | $2.6M | 200K |
| Capricor Therapeutics Inc | CAPR | Shares | $2.4M | 79K |
| Eyepoint Inc | EYPT | Shares | $2.3M | 179K |
| Bicycle Therapeutics Plc | BCYC | Shares | $2.2M | 476K |
| Alumis Inc | ALMS | Call | $2.2M | 100K |
| Indivior Pharmaceuticals Inc | INDV | Shares | $2.2M | 71K |
| Novo-Nordisk A S | NVO | Put | $2.1M | 56K |
| Celcuity Inc | CELC | Call | $2.0M | 18K |
| Climb Bio Inc | CLYM | Shares | $2.0M | 286K |
| Annexon Inc | ANNX | Call | $2.0M | 353K |
| Inventiva Sa | IVA | Shares | $1.9M | 352K |
| Shattuck Labs Inc | STTK | Shares | $1.9M | 294K |
| Liquidia Corporation | LQDA | Put | $1.9M | 50K |
| Tarsus Pharmaceuticals Inc | TARS | Shares | $1.8M | 26K |
| Alkermes Plc | Shares | $1.8M | 50K | |
| Macrogenics Inc | MGNX | Shares | $1.7M | 600K |
| Vertex Pharmaceuticals Inc | VRTX | Shares | $1.7M | 4K |
| Voyager Therapeutics Inc | VYGR | Shares | $1.6M | 424K |
| Replimune Group Inc | REPL | Call | $1.6M | 206K |
| Corvus Pharmaceuticals Inc | CRVS | Call | $1.6M | 106K |
| Cytomx Therapeutics Inc. | CTMX | Call | $1.5M | 316K |
| Anavex Life Sciences Corp | AVXL | Call | $1.5M | 478K |
| Vaxcyte Inc | PCVX | Shares | $1.5M | 25K |
| Relmada Therapeutics Inc | RLMD | Shares | $1.4M | 201K |
| Eyepoint Inc | EYPT | Call | $1.4M | 106K |
| Karyopharm Therapeutics Inc | KPTI | Call | $1.3M | 241K |
| Sellas Life Sciences Group I | SLS | Call | $1.3M | 300K |
| Olema Pharmaceuticals Inc | OLMA | Call | $1.3M | 84K |
| Cormedix Inc | CRMD | Put | $1.1M | 168K |
| Corbus Pharmaceuticals Hldgs | CRBP | Call | $1.1M | 115K |
| Iovance Biotherapeutics Inc | IOVA | Call | $1.1M | 300K |
| Bioage Labs Inc | BIOA | Shares | $1.0M | 60K |
| Inovio Pharmaceuticals Inc | INO | Shares | $979K | 563K |
| Aytu Biopharma Inc | AYTU | Shares | $964K | 353K |
| Equillium Inc | EQ | Shares | $868K | 434K |
| Dianthus Therapeutics Inc | DNTH | Shares | $839K | 10K |
| Pharvaris N V | Shares | $828K | 29K | |
| Enanta Pharmaceuticals Inc | ENTA | Shares | $820K | 65K |
| Immunitybio Inc | IBRX | Put | $815K | 106K |
| Vir Biotechnology Inc | VIR | Call | $796K | 89K |
| Replimune Group Inc | REPL | Shares | $770K | 101K |
| Xeris Biopharma Holdings Inc | XERS | Shares | $770K | 133K |
| Larimar Therapeutics Inc | LRMR | Shares | $750K | 167K |
| Annexon Inc | ANNX | Shares | $736K | 133K |
| Ultragenyx Pharmaceutical In | RARE | Shares | $736K | 35K |
| Mineralys Therapeutics Inc | MLYS | Shares | $714K | 26K |
| Unicycive Therapeutics Inc | UNCY | Shares | $698K | 106K |
| Alumis Inc | ALMS | Put | $687K | 31K |
Values as reported in public regulatory filings (USD); holdings are reported quarterly, up to 45 days after quarter end, and may contain reporting errors. Nothing here is investment advice.